Wednesday, October 14, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 29, 2026

KLA forecasts $4B September-quarter revenue as it lifts 2026 wafer equipment view to low $150B range

View original at seekingalpha.com
KLA forecasts $4B September-quarter revenue as it lifts 2026 wafer equipment view to low $150B range Earnings Call Insights: KLA Corporation (KLAC) Q4 2026 MANAGEMENT VIEW * CEO Richard Wallace said, “For the June quarter, KLA results were strong with revenue, profitability and earnings per share all above the midpoint…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Revenue of $3.66 billion was above the midpoint of guidance of $3.575 billion.

    60% confidence
  • Semiconductor Process Control systems customer mix is expected to be approximately 73% foundry/logic and 27% memory, with memory split approximately 90% DRAM and 10% NAND.

    60% confidence
  • Effective June 11, 2026, KLA completed a 10-for-1 stock split.

    60% confidence
  • Cash flow from operations was $906 million and free cash flow was $817 million; KLA returned $876 million to shareholders, including $571 million in share repurchases and $305 million in dividends.

    60% confidence
  • Second half of calendar 2026 growth for KLA over the first half is anticipated to be approximately 20%.

    60% confidence
  • Momentum is expected to accelerate through the second half of calendar 2026 and significant growth is expected to continue in calendar 2027.

    60% confidence
  • September-quarter gross margin is guided to 62.5%, plus or minus 1 percentage point; operating expenses to approximately $690 million; and EPS to $1.16 non-GAAP and $1.14 GAAP, each plus or minus $0.10.

    60% confidence
  • Memory cost headwinds likely continue through next year but are expected to normalize.

    60% confidence
  • Revenue reached a record $3.66 billion.

    60% confidence
  • The world needs more advanced logic, and the broadening of demand has been happening as hoped.

    60% confidence
  • KLA does not talk about specific customer engagements, declining to discuss SpaceX.

    60% confidence
  • Competitors have been able to ship into fabs in China that KLA hasn't been able to ship into.

    60% confidence
  • Mix is the biggest factor in KLA's gross margin quarter-to-quarter.

    60% confidence
  • KLA is not very good at forecasting.

    60% confidence
  • Some products have lead times closer to 18 to 24 months, and memory pricing impact likely continues through 2027.

    60% confidence
  • Process control is a very high mix, low volume market where KLA's algorithms and 1,600-1,700 worldwide applications engineers give it an advantage; KLA performs well whenever fair competition is allowed.

    60% confidence
  • Memory pricing headwinds to gross margin were around 100 basis points, and probably a bit more than that.

    60% confidence
  • Long lead time optical components can take 12 to 24 months to put new capacity in place.

    60% confidence
  • It's pretty hard to go back to customers after taking orders and start to change prices on those orders.

    60% confidence
  • KLA is raising its expectation for the wafer equipment market, including advanced packaging, to approximately the low $150 billion range in calendar 2026, up from the prior expectation of $140 billion plus, with significant growth planned for calendar 2027.

    60% confidence
  • Services has a long-term target of 13% to 15% growth, with 80% of revenue contract-based, and performance is expected toward the higher end of the range.

    60% confidence
  • KLA ended the quarter with $4.9 billion in total cash, cash equivalents and marketable securities and $5.9 billion of debt.

    60% confidence
  • Input prices have gone up and KLA has had discussions about how it will help capture some of that value.

    60% confidence
  • Non-GAAP diluted EPS was $1.05 and GAAP diluted EPS was $1.04, each at the upper end of the respective guidance ranges.

    60% confidence
  • September-quarter revenue is guided to $4 billion, plus or minus $200 million.

    60% confidence
  • Gross margin of 62.4% was driven by a more favorable services mix than modeled and manufacturing scale, offsetting the challenging memory pricing environment and tariff headwinds.

    60% confidence
  • Since the March Investor Day, demand signals across AI infrastructure have strengthened materially, visibility continues to improve, and the wafer equipment market outlook continues to expand.

    60% confidence
  • Advanced packaging process control systems revenue is now expected to grow to approximately $1.1 billion in calendar 2026, up more than 70% year-over-year.

    60% confidence
  • It is confusing why KLA can't raise prices to at least offset memory prices.

    60% confidence
  • There are very few concerns about 2027 because the build-out clearly continues.

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com